The START Center for Cancer Research

START’s latest article is from the?Medical Independent?featuring START Dublin’s Director of Clinical Research, Dr. Austin Duffy. In this article, Dr. Duffy shares the remarkable journey of bringing early-phase oncology trials to Ireland and the profound impact this work has on patients and their families. Read the article here:?https://lnkd.in/eGv9_RnW ? Reflecting on START Dublin’s mission, Dr. Duffy shares:?"Our goal at START Dublin is to mirror START’s original pragmatic aim here in Ireland: offering access to emerging medicines and the latest science has to offer to those who can’t get them, in the hope that they might provide real benefit to patients with advanced cancer." ? START Dublin is addressing critical gaps in access to emerging cancer treatments, striving to bring the latest science to Irish patients through cutting-edge clinical trials. As the eighth START site globally, START Dublin is proud to contribute to a Site Network that has already led to the approval of 43 cancer therapies by regulatory agencies. ? Interested in learning more about our efforts to expand early-phase trials in Ireland? Schedule a meeting with Dr. Duffy and his team to explore more: https://lnkd.in/eJP9xx8Q. ? #STARTDublin #CancerResearch #ClinicalTrials #HopeThroughAccess ?

We’re excited to share an article authored by Dr. Victor Moreno, Director of Clinical Research at START Madrid-FJD, on the use of wearables in early-phase cancer trials. This work highlights how wearable technology is transforming the way we assess performance status and predict outcomes for patients. Read the article: https://lnkd.in/e4rnQc-V ? Dr. Moreno’s findings demonstrate the potential of Objective Performance Status (OPS), a novel metric derived from wearable data, to improve prognostic accuracy. In one study, patients walking less than 1,200 meters per day had significantly higher mortality rates than those who walked more, making OPS a more reliable predictor of survival than traditional clinician-assessed methods like the ECOG Performance Status. By incorporating wearables into clinical trials, START is helping to provide real-time, objective data for better decision-making and improving access to life-changing therapies. ? We would like to thank the UpSmart Network for the opportunity to present these findings at their recent event.? ? #WearablesInOncology #CancerResearch #ClinicalTrials

We’re headed to San Diego! Join us at the ASH Hematology Conference, December 7-10, where our START hematologists and Principal Investigators, Dr. Daniel Morillo Giles and Dr. Andrew Sochacki, will be in attendance. ? This is your chance to connect with us and learn about the innovative work we’re doing in blood cancers. From early-phase trials to advancing new therapies, we’re pushing the boundaries to bring hope and better outcomes to patients worldwide. ? Let’s set up a time to meet: https://lnkd.in/eCXGPPaF ? #ASH23 #Hematology #BloodCancers #ClinicalResearch

Tune into Dr. Victor Moreno’s recent interview with OncLive to uncover insights into the pharmacodynamic data for CLN-619, a novel humanized IgG1 antibody designed to target MICA and MICB in advanced solid tumors. ? During his discussion, Dr. Moreno, Oncologist & Director of Clinical Research at START Madrid-FJD, sheds light on findings from the ongoing phase 1 trial of CLN-619, both as monotherapy and in combination with pembrolizumab (Keytruda). This data, presented at the 2024 SITC Annual Meeting, showed promising immune responses, including increased T-cell and NK cell activity in responders, supporting the proposed mechanism of action for this innovative therapy. ? Listen to Dr. Moreno’s insights and learn more about how this research is moving us closer to breakthroughs in treating advanced cancers: https://lnkd.in/ePaX_cT8 #oncologyresearch #clinicaltrials #SITC

Our latest expert-led webinar on Malignant Hematology is now available on-demand! If you missed today’s session, now’s your chance to catch up on the complexities of advancing treatments for AML, lymphoma, myeloma, and other malignant hematologic conditions. ? Our panel explored how combination strategies and preclinical data are shaping early combination trials, particularly in AML and myeloid studies. They highlighted the importance of biomarker insights for identifying pathways and optimizing treatment synergy. The session also dove into the challenges of patient recruitment and how sponsor-site collaborations are crucial for trial success. These discussions offered a deep look into the role of collaboration and innovation in advancing patient care. ? Watch the full recording now: https://lnkd.in/gtpX37cS Andrew Sochacki, Gala Vega Achabal, Daniel Morillo Giles, Kathryn Bradford, Nikki Daskalakis, Hugo O. #hematology #clinicalresearch #clinicaltrials

We're thrilled to announce that Dr. Drew Rasco at START San Antonio has successfully dosed the first patient in Nammi Therapeutics, Inc. QXL138AM trial—a Phase 1 study targeting advanced solid tumors and multiple myeloma. ? Reflecting on the milestone, Dr. Rasco shared, "We're very excited to have dosed the first patient with QXL138AM here at START. We believe that there is significant potential with Nammi's immunocytokine technology in the treatment of multiple cancer types, and we look forward to working with the Nammi team to develop this new therapy over the coming years." ? This marks a major step forward in our mission to advance innovative cancer therapies. Read Nammi’s press release to learn more about this exciting collaboration with Nammi Therapeutics and our shared commitment to bringing hope to patients through cutting-edge research: https://lnkd.in/eE2WU32i #clinicaltrials #oncology

Hello, Houston! We’re thrilled to be at the SITC conference this week with several thought leadership presentations from our PIs. Dr. Manish R. Sharma, Dr. Nehal Lakhani, and Dr. Kyriakos Papadopoulos will each be showcasing their latest research through oral and poster presentations. If you’re at SITC, stop by the sessions to dive into their findings, or swing by to meet with our team and discuss opportunities for collaboration. We look forward to connecting and sharing insights with the oncology and immunology community here at SITC! #SITC #oncologyresearch #immunology #clinicaltrials

Just a few days left! https://lnkd.in/edJU-Hn2 Join us next Wednesday for an expert-led discussion on malignant hematology! This webinar brings together thought leaders in the field, including new speakers from J&J: Dr. Kathryn Bradford, Dr. Nikki Daskalakis, and Hugo O., who will be presenting alongside our own START PIs: Dr. Andrew Sochacki, Dr. Daniel Morillo Giles, and Dr. Gala Vega Achabal. Don’t miss this opportunity to gain insights on the evolution of hematologic clinical trials, and the current research in lymphoma, AML, multiple myeloma, and cell therapies, and the challenges and innovations shaping patient outcomes in these complex diseases. Register today to secure your spot: https://lnkd.in/edJU-Hn2 #hematology #clinicalresearch

What pressing questions are top of mind for researchers exploring bispecific antibodies? Our recent #BsAb webinar sparked incredible discussions around complex topics, including: 1) Challenges in trial design for these novel therapies, 2) Immunogenic responses and potential patient risks, 3) Managing cytokine storms during treatment, 4) Addressing T-cell exhaustion for sustained efficacy …and so much more! Curious to dive deeper? Submit your questions to [email protected] and let’s keep advancing the conversation on bispecific antibodies. Drew Rasco, William McKean, André Mansinho, Teresa Ramirez Montagut MD,PhD #bispecificantibodies #oncologyresearch #clinicaltrials

An amazing job by everyone and a pleasure and privilege to be working in this very special space - on behalf of the START Dublin team thank you!